Our innovative products and technologies define a new era in current and future diagnostic and therapeutic radiopharmaceuticals.
We lead the way in producing stable, reliable, domestically-sourced, environmentally-friendly radioisotope supply to meet critical patient healthcare needs and advance clinical research.
Our people drive our solutions in advancing radioisotope technology to shape a better world.
We are a recognized, emerging global leader with a proven track record and strong vision for the future of radiopharmaceuticals. Our innovation-driven technology is transforming the landscape for medical radioisotope production and distribution around the world.
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Truist Securities Biopharma Symposium
Read More >NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
Read More >First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma
Read More >NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium‐225 (Ac‐225)
Read More >